HONG KONG – In a move that will give its parent group a debut listing in the U.S., South Korean biotech company Samsung Bioepis said it will aim for a Nasdaq listing.
HONG KONG – In a move that will give its parent group a debut listing in the U.S., South Korean biotech company Samsung Bioepis said it will aim for a Nasdaq listing.
HONG KONG – Disaster preparedness isn't a topic that shows up in frequent biopharma discussions or on conference agendas, but the powerful typhoon that hit Taiwan and Mainland China earlier this month – killing at least 34 people, damaging 65,000 homes and leaving more than 4 million homes without power – highlighted the importance of emergency preparedness for companies in the biopharma space, particularly when setting up shop in a country that is regularly assailed by huge storms and occasional earthquakes.
HONG KONG – Disaster preparedness isn't a topic that shows up in frequent biopharma discussions or on conference agendas, but the powerful typhoon that hit Taiwan and Mainland China earlier this month – killing at least 34 people, damaging 65,000 homes and leaving more than 4 million homes without power – highlighted the importance of emergency preparedness for companies in the biopharma space, particularly when setting up shop in a country that is regularly assailed by huge storms and occasional earthquakes.
HONG KONG – Recovering from an acquisition bid in June that ultimately sent its shares down by about 20 percent, Chinese drugmaker Luye Pharma Group Ltd. is back on the deal trail, this time with plans to acquire Singapore-based molecular diagnostics firm Vela Diagnostics Pte Ltd.
HONG KONG – Recovering from an acquisition bid in June that ultimately sent its shares down by about 20 percent, Chinese drugmaker Luye Pharma Group Ltd. is back on the deal trail, this time with plans to acquire Singapore-based molecular diagnostics firm Vela Diagnostics Pte Ltd.
